98%
921
2 minutes
20
Amyotrophic lateral sclerosis (ALS) leads to death within 2-5 yr. Currently, available drugs only slightly prolong survival. We present novel insights into the pathophysiology of (SOD1)- and in particular (FUS)-ALS by revealing a supposedly central role of glycolic acid (GA) and D-lactic acid (DL)-both putative products of the Parkinson's disease associated glyoxylase DJ-1. Combined, not single, treatment with GA/DL restored axonal organelle phenotypes of mitochondria and lysosomes in FUS- and SOD1-ALS patient-derived motoneurons (MNs). This was not only accompanied by restoration of mitochondrial membrane potential but even dependent on it. Despite presenting an axonal transport deficiency as well, TDP43 patient-derived MNs did not share mitochondrial depolarization and did not respond to GA/DL treatment. GA and DL also restored cytoplasmic mislocalization of FUS and FUS recruitment to DNA damage sites, recently reported being upstream of the mitochondrial phenotypes in FUS-ALS. Whereas these data point towards the necessity of individualized (gene-) specific therapy stratification, it also suggests common therapeutic targets across different neurodegenerative diseases characterized by mitochondrial depolarization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101837 | PMC |
http://dx.doi.org/10.26508/lsa.202302535 | DOI Listing |
Turk J Pharm Sci
September 2025
Gate Institute of Pharmaceutical Sciences, Telangana, India.
Objectives: Bortezomib (BTZ) functions as an androgen receptor signalling inhibitor, is used for the treatment of prostate cancer, and has been sanctioned by the United States Food and Drug Administration. The medicinal applications of BTZ are impeded by low solubility, first-pass metabolism, and restricted bioavailability. This study aimed to develop and enhance polylactic acid-co-glycolic acid (PLGA) nanobubbles (NBs) as a sustained-release mechanism for BTZ, thereby augmenting stability and bioavailability.
View Article and Find Full Text PDFNanomedicine
September 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S
Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.
View Article and Find Full Text PDFInt J Pharm
September 2025
Department of Chemistry, Adithya Institute of Technology, Coimbatore 641107 Tamil Nadu, India.
Chronic wounds are a foremost cause of death, affecting 6.5 million people annually. Traditional treatments, such as metal-based formulations and biomaterials, are ineffective due to their toxicity and the rising incidence of chronic wound cases, necessitating the advancement of new therapies for efficient wound healing.
View Article and Find Full Text PDFJ Drugs Dermatol
September 2025
The accumulation of endogenous advanced glycation end products (AGEs) has been shown to degrade the integrity of the extracellular matrix in the dermis, resulting in signs of aging. Resurfacing procedures are a first-line treatment option. Post-procedure skin care is integral in achieving optimal results with minimal downtime.
View Article and Find Full Text PDFJ Biochem Mol Toxicol
September 2025
Department of Biology, SR.C., Islamic Azad University, Tehran, Iran.
Among cancers, liver cancer is the fourth leading cause of mortality worldwide and drawbacks of conventional approaches could not inhibit this cancer. Thus, an efficient folic acid (FA)-functionalized chitosan (CS)-poly lactic-co-glycolic acid (PLGA) nanocarrier was fabricated for delivery of sodium butyrate (NB) therapeutics to HepG2 liver cancer cells. The fabricated CS-NB-PLGA-FA nanocarrier was characterized by FT-IR, DLS, TEM, and TGA.
View Article and Find Full Text PDF